RCS - Medpal AI PLC - Initiation of research

Medpal AIAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251103:nRSC8608Fa&default-theme=true

RNS Number : 8608F  Medpal AI PLC  03 November 2025

REACH non-regulatory announcement

3 November 2025

MedPal AI plc

(the "Company" or "MedPal AI")

Initiation of Research by Optimo Research

MedPal AI plc (AIM:MPAL), a UK-based digital health and artificial
intelligence (AI) company is pleased to announce the initiation of research by
Optimo Capital Limited's research arm, Optimo Research Ltd ("Optimo
Research").

The research is available on the Optimo Research website here:

https://www.optimocapital.co.uk/library-2
(https://www.optimocapital.co.uk/library-2)

For further information please visit www.medpalplc.com
(http://www.medpalplc.com) or contact:

 

MedPal AI plc
                            via Square1 Consulting

 

Jason Drummond, Chief Executive Officer

 

Clear Capital Markets Limited
              +44 20 3869 6080

Bob Roberts/ Nick Josh

 

Square1 Consulting
                                    +44 20
7929 5599

David Bick
 
+44 7831 381201

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearable
health trackers and apps (eg. Apple Health, Fitbit or Garmin) into a unified
profile, offering non-clinical, personalised lifestyle guidance through its AI
wellness coach. The Company is also developing conversational AI to provide
voice-based, real-time health Insights, alerts and recommendations.

MedPal AI recently acquired a complementary automated pharmacy facility,
operating under an NHS Distance Selling Pharmacy licence, to deliver timely,
affordable access to medicine and telehealth pathways across the UK.

 

Visit our website: www.medpalplc.com (http://www.medpalplc.com)

 

Follow us on social media:

X: @MedPalPlc

LinkedIn: MedPal AI plc

 

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only/non-regulatory news releases Into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or any other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAVLLFBEFLZFBK



            Copyright 2019 Regulatory News Service, all rights reserved